Archives
- 2026-04
- 2026-03
- 2026-02
- 2026-01
- 2025-12
- 2025-11
- 2025-10
- 2025-09
- 2025-03
- 2025-02
- 2025-01
- 2024-12
- 2024-11
- 2024-10
- 2024-09
- 2024-08
- 2024-07
- 2024-06
- 2024-05
- 2024-04
- 2024-03
- 2024-02
- 2024-01
- 2023-12
- 2023-11
- 2023-10
- 2023-09
- 2023-08
- 2023-07
- 2023-06
- 2023-05
- 2023-04
- 2023-03
- 2023-02
- 2023-01
- 2022-12
- 2022-11
- 2022-10
- 2022-09
- 2022-08
- 2022-07
- 2022-06
- 2022-05
- 2022-04
- 2022-03
- 2022-02
- 2022-01
- 2021-12
- 2021-11
- 2021-10
- 2021-09
- 2021-08
- 2021-07
- 2021-06
- 2021-05
- 2021-04
- 2021-03
- 2021-02
- 2021-01
- 2020-12
- 2020-11
- 2020-10
- 2020-09
- 2020-08
- 2020-07
- 2020-06
- 2020-05
- 2020-04
- 2020-03
- 2020-02
- 2020-01
- 2019-12
- 2019-11
- 2019-10
- 2019-09
- 2019-08
- 2019-07
- 2019-06
- 2019-05
- 2019-04
- 2018-11
- 2018-10
- 2018-07
-
These findings suggest that eventually more than one
2023-08-02

These findings suggest that eventually more than one 12/15-lipoxygenase isoform may play a role in human atherosclerosis. Humans have two 12-lipoxygenases and two 15-lipoxygenases which show different expression patterns, substrate specificities and stereo-selective metabolism [1]. However, in Bisin
-
BI-9564 Imatinib was first approved for the treatment of Phi
2023-08-02

Imatinib was first approved for the treatment of Philadelphia chromosome positive chronic myelogenous leukemia in 2001 [25]. This first approved small molecule antagonist is quite unusual in that it provides a durable response that lasts for more than a decade in the majority of patients. Imatinib h
-
VEGFR Tyrosine Kinase Inhibitor II Alectinib is a second gen
2023-08-02

Alectinib is a second generation ALK antagonist that is built upon a 9-ethyl-6, 6-dimethyl-11-oxo benzo[b]carbazole scaffold (Fig. 5C) [58]. This drug is effective against the ALK L1196M gatekeeper mutation along with C1156Y and F1174L mutations [7]. The 11-oxo group of the drug forms a VEGFR Tyrosi
-
br Materials and Methods br Results In the Base Analysis
2023-08-02

Materials and Methods Results In the Base Analysis (53% of patients having access to the ALK test in both Current and Alternative Scenarios), a total of 16,583 patients were tested of whom 1,252 were assumed to be ALK-positive. A more extensive use of Ventana in the Alternative Scenario determ
-
br Materials and methods br Results br Discussion Wound heal
2023-08-02

Materials and methods Results Discussion Wound healing of the human cornea is a complex process that requires cell migration and proliferation. Corneal wound healing is characterized by major changes in the composition of the ECM such as a massive transitory secretion of fibronectin combine
-
It is also possible that adrenoceptor activation may
2023-08-02

It is also possible that α2-adrenoceptor activation may inhibit glutamate accumulation by upregulating the glutamate-buffering activity of Müller BAY-73 mg through EAAT1 or adjusting EAAT2 in bipolar cells, as well as the NMDA receptor. Therefore, we investigated whether topical administration of b
-
Blockers will reduce perioperative myocardial ischemia and s
2023-08-02

β-Blockers will reduce perioperative myocardial ischemia and studies published in the 1990s suggested that their routine administration before surgery provided protection against perioperative CV complications.31., 32., 33. Based on these early studies, several national organizations endorsed the pe
-
APN accounts for of total
2023-08-02

APN accounts for 0.01% of total plasma proteins in humans; this proportion increases with age to a small extent (Barb et al., 2007). Normal APN levels in the circulation range 3–30μg/mL (Aprahamian and Sam, 2011). APN levels are lower in men than women due to the presence of testosterone and even mo
-
We have previously shown that the human gonadotropins
2023-08-02

We have previously shown that the human gonadotropins hLH and hCG trigger a partly irreversible stimulation of intracellular cyclic AMP accumulation in mouse Leydig Tumor MI-77301 (MLTC) in contrast to all other tested mammalian LHs and CG (Klett et al., 2016). In order to get a better insight in t
-
br Methods br Results br Discussion First the
2023-08-02

Methods Results Discussion First, the 3606 mg isolated from non-PD TA tissue and PD plaque tissue were characterized. The results showed that both cell groups were positive for vimentin and negative for desmin suggesting that these cells were fibroblasts. It was also observed that treatmen
-
It has been reported that leukotrienes and
2023-08-01

It has been reported that leukotrienes and their receptors, e.g. the cysteinyl leukotriene receptor 1 (CysLT1) may promote NHS-12-Biotin injury (Ding et al., 2007) and that increased 5-LOX expression and activity lead to production of brain-toxic molecules (Khan et al., 2010). However, differential
-
The c C T mutation identified in subject
2023-08-01

The c.286C>T mutation identified in subject K20-1 was also reported in other ethnic groups, including Brazilian, French-Canadian, Italian, and Arabs from the United Arab Emirates [20], [21], [22], whereas c.318A>G mutation in subjects K10-1 was previously reported in Asian and Caucasians [13], [23],
-
br Materials and methods br Results br Discussions Our resul
2023-08-01

Materials and methods Results Discussions Our results indicated that autophagy was suppressed in GECs under HAGG treatment, through Akt/mTOR-dependent pathways. Previous reports provided clues for the linkages between ICs and endothelial cell autophagy. Fujii and colleagues reported that se
-
Protein protein interaction networks are an
2023-08-01

Protein–protein interaction networks are an important ingredient for the system-level understanding of cellular processes. Such networks can be used for filtering and assessing functional genomics data and for providing an instinctive platform for annotating structural, functional and evolutionary p
-
BPTES mg Whole body loss of ACLY is early embryonic lethal i
2023-08-01

Whole-body loss of ACLY is early embryonic lethal, indicating that it serves non-redundant roles during development (Beigneux et al., 2004). Silencing or inhibition of ACLY suppresses the proliferation of many cancer cell lines and impairs tumor growth (Bauer et al., 2005, Hanai et al., 2012, Hatziv
16785 records 332/1119 page Previous Next First page 上5页 331332333334335 下5页 Last page